Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.
Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...
Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...
Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...
Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...
In the latest market close, Vertex Pharmaceuticals (VRTX) reached $409.56, with a -0.62% movement compared to the previous day. This change was narrower than the S&P 500's 1.54% loss on the day.
Vertex Pharmaceuticals' estimated fair value is US$708 based on 2 Stage Free Cash Flow to Equity Vertex Pharmaceuticals is estimated to be 42% undervalued based on current share price of US$412 ...
Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...
Vertex Pharmaceuticals Incorporated (VRTX), headquartered in Boston, Massachusetts, is a global leader in biotechnology and precision medicine. With a market cap of $106.1 billion, Vertex ...
Ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) were provided by 23 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a concise ...
Vertex Pharmaceuticals Inc. will work with a Watertown biotech on new gene-editing therapies for people with sickle cell disease and transfusion-dependent beta thalassemia. A Watertown biotech is ...
In the latest market close, Vertex Pharmaceuticals (VRTX) reached $409.56, with a -0.62% movement compared to the previous day. This change was narrower than the S&P 500's 1.54% loss on the day.